10-K · February 26, 2026
Edgewise positions itself as a muscle‑focused precision medicines company leveraging a proprietary drug discovery platform to advance small‑molecule sarcomere modulators. The company’s lead program, sevasemten, is in…
Earnings analysis · 10-Q
EWTX earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Edgewise Therapeutics continues to incur significant losses, reporting a net loss of $49.0 million for Q1 2026 compared to $40.8 million in Q1 2025. Operating expenses have increased by 17.7% year-over-year, driven by…
Read full summary
Edgewise Therapeutics continues to incur significant losses, reporting a net loss of $49.0 million for Q1 2026 compared to $40.8 million in Q1 2025. Operating expenses have increased by 17.7% year-over-year, driven by higher research and development costs. The company expects to maintain its current cash reserves of $499.6 million for at least the next 12 months to support ongoing development activities and clinical trials.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Rising Net Losses
Net loss increased to $49.0 million in Q1 2026 from $40.8 million in Q1 2025.
-
Significant Cash Position
As of March 31, 2026, the company holds $499.6 million in cash, cash equivalents, and marketable securities.
-
Increased R&D Spending
Research and development expenses rose to $42.7 million from $36.8 million year-over-year, reflecting a 14.1% increase.
-
Interest Income Stable
Interest income was $5.1 million for Q1 2026, slightly down from $5.2 million in Q1 2025.
-
Continued Clinical Trials
The lead product, sevasemten, remains in multiple late-stage clinical trials as per ongoing development plans.
-
Potential for Capital Raises
Management has indicated the plan to engage in additional equity offerings for funding, leaning on the $175 million available through the ATM program.
What to watch
-
Widening Operational Losses
Company continues pre-revenue status, with ongoing losses signaling potential unsustainable cash burn.
-
Dependence on Third-Party Collaborators
Clinical trials are conducted via third-party CROs which may not perform satisfactorily, indicating execution risk.
-
Regulatory and Market Risks
Uncertainties in obtaining regulatory approvals for therapies could prolong development timelines and affect revenue generation.
Management's outlook
Management expects to maintain sufficient funding through current resources but is open to future equity offerings.
Earlier filings 4
10-Q · November 6, 2025
Edgewise reported a Q3 2025 net loss of $40,666 (EPS -$0.39), wider than Q3 2024 net loss of $34,129 (EPS -$0.36) driven by higher R&D and G&A. Cash and marketable securities totaled $563.3 million as of September 30,…
10-Q · August 7, 2025
Edgewise remains pre-revenue and reported a net loss of $36,115,000 for the three months ended June 30, 2025 (EPS -$0.34), compared with a net loss of $31,497,000 (EPS -$0.34) in the prior-year quarter. The company…
10-K · March 3, 2025
Edgewise Therapeutics is a clinical-stage, muscle-focused biotech advancing two lead programs: sevasemten (EDG-5506) in multiple Phase 2 trials including the pivotal GRAND CANYON cohort and EDG-7500 in a multi-part…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.